Daniel Olive MD, PhD.,
D. Olive, after a training in Internal Medicine, he is currently Professor of Immunology at Aix Marseille University and Institut Paoli Calmettes, he is also in charge of the « Immunity and Cancer » research team of INSERM UMR1068 of Marseille Cancer Research Center . He is the head of the first IBiSA Platform dedicated to Cancer Immunomonitoring Platform.
D. Olive has been a pioneer and leader in the co-signalling field since 1990. His work is dedicated to tumor immunology with a major emphasis on innate immunity and co-signalling molecules.
Selected major breakthroughs:
1) Identification of signaling pathways involved in CD28 and ICOS costimulatory molecules;
2) Demonstration that BTN3A1/CD277 is a major inducer of Vg9Vd2 response;
3) identification of the function of BTLA and HVEM in the regulation of immune function;
4) identification of HVEM and BTLA as escape mechanisms in melanoma and non hodgkin lymphoma;
5) Identification of molecular mechanisms associated to NK cells impairment in AML patients;
6) first identification of alteration of NK cells in the tumor bed in breast cancer;
7) First in man clinical trial using anti-KIR mAbs in AML patients;
8) demonstration of the targeting of pDC by HCV;
9) Deciphering of of ICOS ICOSL interaction in the regulation of Tregs in lymphomas.
They are experts in the field of investigations on innate cells within tumor microenvironment.
He is actively involved in translating discoveries to Biotech that he has either co-founded (Imcheck Therapeutics, Emergence Therapeutics , Alderaan Biotechnology) as well as out-licensing patents to pharmas (ICOS to GSK and CD277 to Imcheck Therapeutics that are currently in clinical trial phase2-3 and phase1 respectively)